Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis

P. C. Lai, M. S. Wu, J. Y. Huang, C. C. Huang, M. L. Leu

Research output: Contribution to journalArticle

Abstract

We carried out our study with 54 hemodialysis patients and 11 CAPD patients. The hemodialysis patients were divided into five groups. Group 1 and group 2 received intermediate doses of erythropoietin ranging from 150 U/Kg/wk to 180 U/Kg/wk. Group 3, group 4 and group 5 received low doses of erythropoietin ranging from 75 U/Kg/wk to 90 U/Kg/wk. While group 1 and group 4 received erythropoietin subcutaneously, group 2 and group 3 received erythropoietin intravenously. The CAPD patients all received subcutaneous erythropoietin. The efficacy of the erythropoietin therapy was evaluated by (1) the early response rate, (2) the late response rate, (3) the time to reach the target hematocrit, (4) the therapeutic cumulative dose, and (5) the maintenance dose. We concluded that: (1) dose is the prime factor determining the rate and ratio of patients response to erythropoietin. (2) subcutaneous administration is more effective than the intravenous route resulting in a 20% to 30% dose-reduction effect, and (3) CAPD patients had a better erythropoietin response than the hemodialysis patients. A larger study is necessary to confirm this finding.

Original languageEnglish
Pages (from-to)105-112
Number of pages8
JournalChang Gung Medical Journal
Volume17
Issue number2
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Continuous Ambulatory Peritoneal Dialysis
Erythropoietin
Renal Dialysis
Hematocrit
Therapeutics

Keywords

  • CAPD
  • erythropoietin
  • hemodialysis
  • uremia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis. / Lai, P. C.; Wu, M. S.; Huang, J. Y.; Huang, C. C.; Leu, M. L.

In: Chang Gung Medical Journal, Vol. 17, No. 2, 1994, p. 105-112.

Research output: Contribution to journalArticle

@article{12df35dcdfea40f6bbc3026986c050f7,
title = "Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis",
abstract = "We carried out our study with 54 hemodialysis patients and 11 CAPD patients. The hemodialysis patients were divided into five groups. Group 1 and group 2 received intermediate doses of erythropoietin ranging from 150 U/Kg/wk to 180 U/Kg/wk. Group 3, group 4 and group 5 received low doses of erythropoietin ranging from 75 U/Kg/wk to 90 U/Kg/wk. While group 1 and group 4 received erythropoietin subcutaneously, group 2 and group 3 received erythropoietin intravenously. The CAPD patients all received subcutaneous erythropoietin. The efficacy of the erythropoietin therapy was evaluated by (1) the early response rate, (2) the late response rate, (3) the time to reach the target hematocrit, (4) the therapeutic cumulative dose, and (5) the maintenance dose. We concluded that: (1) dose is the prime factor determining the rate and ratio of patients response to erythropoietin. (2) subcutaneous administration is more effective than the intravenous route resulting in a 20{\%} to 30{\%} dose-reduction effect, and (3) CAPD patients had a better erythropoietin response than the hemodialysis patients. A larger study is necessary to confirm this finding.",
keywords = "CAPD, erythropoietin, hemodialysis, uremia",
author = "Lai, {P. C.} and Wu, {M. S.} and Huang, {J. Y.} and Huang, {C. C.} and Leu, {M. L.}",
year = "1994",
language = "English",
volume = "17",
pages = "105--112",
journal = "Chang Gung Medical Journal",
issn = "0255-8270",
publisher = "Chang Gung Medical Journal",
number = "2",

}

TY - JOUR

T1 - Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis

AU - Lai, P. C.

AU - Wu, M. S.

AU - Huang, J. Y.

AU - Huang, C. C.

AU - Leu, M. L.

PY - 1994

Y1 - 1994

N2 - We carried out our study with 54 hemodialysis patients and 11 CAPD patients. The hemodialysis patients were divided into five groups. Group 1 and group 2 received intermediate doses of erythropoietin ranging from 150 U/Kg/wk to 180 U/Kg/wk. Group 3, group 4 and group 5 received low doses of erythropoietin ranging from 75 U/Kg/wk to 90 U/Kg/wk. While group 1 and group 4 received erythropoietin subcutaneously, group 2 and group 3 received erythropoietin intravenously. The CAPD patients all received subcutaneous erythropoietin. The efficacy of the erythropoietin therapy was evaluated by (1) the early response rate, (2) the late response rate, (3) the time to reach the target hematocrit, (4) the therapeutic cumulative dose, and (5) the maintenance dose. We concluded that: (1) dose is the prime factor determining the rate and ratio of patients response to erythropoietin. (2) subcutaneous administration is more effective than the intravenous route resulting in a 20% to 30% dose-reduction effect, and (3) CAPD patients had a better erythropoietin response than the hemodialysis patients. A larger study is necessary to confirm this finding.

AB - We carried out our study with 54 hemodialysis patients and 11 CAPD patients. The hemodialysis patients were divided into five groups. Group 1 and group 2 received intermediate doses of erythropoietin ranging from 150 U/Kg/wk to 180 U/Kg/wk. Group 3, group 4 and group 5 received low doses of erythropoietin ranging from 75 U/Kg/wk to 90 U/Kg/wk. While group 1 and group 4 received erythropoietin subcutaneously, group 2 and group 3 received erythropoietin intravenously. The CAPD patients all received subcutaneous erythropoietin. The efficacy of the erythropoietin therapy was evaluated by (1) the early response rate, (2) the late response rate, (3) the time to reach the target hematocrit, (4) the therapeutic cumulative dose, and (5) the maintenance dose. We concluded that: (1) dose is the prime factor determining the rate and ratio of patients response to erythropoietin. (2) subcutaneous administration is more effective than the intravenous route resulting in a 20% to 30% dose-reduction effect, and (3) CAPD patients had a better erythropoietin response than the hemodialysis patients. A larger study is necessary to confirm this finding.

KW - CAPD

KW - erythropoietin

KW - hemodialysis

KW - uremia

UR - http://www.scopus.com/inward/record.url?scp=0028070509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028070509&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 105

EP - 112

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

SN - 0255-8270

IS - 2

ER -